Please assess the completion status of the following clinical trial:

Trial Title: To Investigate the Safety and Efficacy of UB-421 Monotherapy in HIV Infected Adults

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HIV-1 sero-positive~* Aged 20 years or older~* Have received HAART treatment~* CD4+ T cell count ≧ 350 cells/mm3~* HIV-1 plasma RNA level remains below the limit of~* Were not breastfeeding for women~* Subjects with a negative serum pregnancy test result at screening visit for women of childbearing potential~* Subjects agree on using birth control barrier (female or male condom) during the entire study period~* Subjects sign the informed consent before undergoing any study procedures~Exclusion Criteria:~* Any active infection except for HIV, and required immediate therapy~* Any active AIDS-defining illness per Category B and Category C conditions according to the U.S. Centers for Disease Control and Prevention (CDC) Classification System for HIV Infection~* Any documented CD4+ T cell count \< 200 cells/mm3 within the past 12 weeks before screening visit~* Any significant diseases (other than HIV-1 infection) or clinically significant findings, including psychiatric and behavioral problems, determined from screening, medical history, and/or physical examination that, in the investigator's opinion, would preclude the subject from participating in this study~* Any vaccination within 8 weeks prior to the first dose of study drug~* Any immunomodulating therapy (including interferon and steroid) or systemic chemotherapy within 12 weeks prior to the first dose of study drug~* Any illicit intravenous drugs within 12 weeks prior to the first dose of study drug~* Any current alcohol or illicit drug use that, in the investigator's opinion, will interfere with the subject's ability to comply with the dosing, visit schedules and protocol evaluations~* More than one change of HAART regimen because of virologic failure

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- cohort 1 (Type: EXPERIMENTAL): Subjects will receive 8 doses of the UB-421 by intravenous infusion at 10 mg/kg weekly
- cohort 2 (Type: EXPERIMENTAL): Subjects will receive 8 doses of the UB-421 by intravenous infusion at 25 mg/kg weekly

Based on this trial design, predict the completion outcome and termination type (if applicable).